Nucleoside analogues for chronic hepatitis B

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 12, 2001, Pages 1499-1506

  Wolters, Leonieke M M ^a   Niesters, Hubert G M ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Entecavir; Famciclovir; Ganciclovir; Lamivudine; Molecular biology; Resistance; Toxicity

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CYTOTOXICITY; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVIEW; TREATMENT PLANNING; VIRUS REPLICATION;

2-AMINOPURINE; ADENINE; ANTIVIRAL AGENTS; GANCICLOVIR; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035217084     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200112000-00016     Document Type: Review

References (62)

1. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
2. Analysis of the earliest steps of hepadnavirus replication: Genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity
3. DNA polymerase activity of hepatitis B virus particles: Differential inhibition by L-enantiomers of nucleotide analogs
4. Lamivudine (3TC) phosphorylation and drug interactions in vitro
5. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine
6. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
7. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription
8. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus
9. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase
10. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir
11. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
12. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
13. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
14. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus
15. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo
16. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: Effect on intrahepatic-viral DNA, RNA, and protein expression
17. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue
18. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
19. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates
20. Structure of hepatitis B Dane particle DNA and nature of the endogenous DNA polymerase reaction
21. Replication of the genome of a hepatitis-like virus by reverse transcription of an RNA intermediate
22. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA
23. The guanine nucleoside analog penciclovir is active against chronic hepatitis B virus infection in vivo
24. Maintenance of viral suppression in chronically infected woodchucks with weekly dosing of BMS 200.475
25. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA
26. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
27. Mitochondrial injury. Lessons from the fialuridine trial
28. The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′fluoro-1-β-D-arabinofuranosyl-5-iodo) uracil] is selective, reversible, and determined, at least in part, by the host cell
29. Mammalian DNA polymerase α, β, γ, δ, and ε incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate
30. Eukaryotic DNA polymerases
31. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ
32. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′ triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerase alpha, beta and gamma
33. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ
34. Crystal structure of human immunodeficiency virus type I reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA
35. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
36. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
37. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
38. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
39. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
40. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
41. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
42. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
43. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
44. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
45. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene
46. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
47. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
48. Bi-phasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
49. Contrasting patterns of response to lamivudine monotherapy
50. A combinatorial ledge; reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
51. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
52. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
53. A one-year trial of lamivudine for chronic hepatitis B
54. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
55. Lamivudine as initial treatment for chronic hepatitis B in the United States
56. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection
57. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
58. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
59. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
60. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
61. Bi-phasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
62. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis